)
)
)
YOU SHOULD ATTEND:
Navigating the New Normal: Venture Investment Trends
HSBC’s mid-year report signaled the challenges that many small and mid-sized biotech companies have shared; first financings declined in Q2 of 2025 and entrepreneurs and companies have had to make tough staffing decisions and adjust their pipelines and programs. While interest rates have started to lower, macroeconomic uncertainties remain in addition to the risk embedded in developing novel medicines. This session will begin with an overview of financing in 2025 followed by a discussion on how companies and investors have remained nimble. The role of venture capital and how family offices are participating in financing will also be featured.
YOU SHOULD ATTEND:
Bankers, Investors, and Biotech: What Would IPO Success in 2026 Require?
The pace of US biotech IPOs stalled for much of 2025 but reductions in interest rates corelate with an uptick in new offerings as investors reconsider the risks and returns from new medicines in this dynamic commercial landscape. This session will examine which technologies, therapeutic areas, and types of messages are most resonating with IPO investors.
YOU SHOULD ATTEND:
Up Next: M&A and Licensing in the Year Ahead?
While deal volumes have adjusted following the influx of capital during the pandemic, there has still been significant activity as pharma continues to assess overall strategy and biotech companies seek partners to continue progress in the clinic with the goal of commercialization. An overview presentation on deal trends will open this discussion, followed by pharma BD leaders and biotech companies that have partnered with them to offer perspective on navigating the complexities of dealmaking.